## Christina Dold

## List of Publications by Year

 in descending orderSource: https:/|exaly.com/author-pdf/8289066/publications.pdf
Version: 2024-02-01


| 1 | T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. Lancet Microbe, The, 2022, 3, e21-e31. | 3.4 | 131 |
| :---: | :---: | :---: | :---: |
| 2 | Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. JCI Insight, 2022, 7, . | 2.3 | 24 |
| 3 | Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891. | 6.3 | 979 |
| 4 | T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nature Communications, 2021, 12, 2055. | 5.8 | 102 |
| 5 | Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, The, 2021, 397, 1351-1362. | 6.3 | 540 |
| 6 | Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. Nature Communications, 2021, 12, 5061. | 5.8 | 150 |
| 7 | Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell, 2021, 184, 5699-5714.e11. | 13.5 | 262 |
| 8 | Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, The, 2020, 396, 467-478. | 6.3 | 2,080 |
| 9 | Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993. | 6.3 | 1,196 |

